Vicebio’s ‘Molecular Clamp’ technology to bolster Sanofi’s respiratory vaccine pipeline targeting RSV and hMPV
French pharmaceutical giant Sanofi has signed a definitive agreement to acquire Vicebio, a UK-based biotechnology firm specializing in respiratory virus vaccines, in a deal valued at up to $1.6 billion. This strategic acquisition strengthens Sanofi’s position in next-generation vaccine development and expands its footprint in the global respiratory vaccine market.
According to the agreement, Sanofi will pay $1.15 billion upfront, with an additional $450 million in milestone-based payments, dependent on regulatory and clinical achievements. The deal is expected to close in the fourth quarter of 2025, pending customary regulatory approvals and closing conditions.
Molecular Clamp Technology: A Game-Changer in Vaccine Development
The acquisition gives Sanofi full access to Vicebio’s proprietary ‘Molecular Clamp’ platform, a cutting-edge biotechnology that stabilizes viral proteins in their native form. This enables the immune system to recognize and respond to infections more effectively.
This platform is designed to facilitate the development of:
-
Fully liquid combination vaccines
-
Prefilled syringe-compatible formulations
-
Vaccines that are stable at standard refrigeration temperatures
These features are expected to streamline distribution, simplify logistics, and improve vaccine accessibility, especially in low-resource settings.
Strengthening the Respiratory Vaccine Portfolio
Vicebio’s vaccine pipeline includes two promising candidates:
-
VXB-241: A bivalent vaccine candidate targeting RSV (Respiratory Syncytial Virus) and hMPV (Human Metapneumovirus), currently in Phase 1 clinical trials in older adults.
-
VXB-251: A preclinical trivalent vaccine candidate targeting RSV, hMPV, and Parainfluenza Virus Type 3 (PIV3).
These candidates align with Sanofi’s existing respiratory vaccine programs and reinforce its commitment to combination vaccines and non-mRNA platforms, expanding therapeutic options for both physicians and patients.
“Vicebio’s ‘Molecular Clamp’ technology introduces a purposefully simple but thoughtful approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally,” said Jean-François Toussaint, Global Head of Vaccines R&D at Sanofi. “This acquisition furthers Sanofi’s dedication to vaccine innovation with the potential to deliver next-generation combination vaccines in a single immunization.”
Strategic Fit and Industry Impact
The acquisition of Vicebio supports Sanofi’s broader strategic goal of accelerating innovation in the infectious disease and respiratory vaccine markets. By acquiring a platform that can be rapidly adapted for new pathogens, Sanofi also strengthens its capabilities in pandemic preparedness.
“We are excited to join Sanofi,” said Emmanuel Hanon, CEO of Vicebio. “Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology. As part of the Sanofi team, we look forward to advancing our platform and delivering meaningful benefits for patients and public health.”
Looking Ahead
As the healthcare industry continues to face challenges from seasonal respiratory viruses and emerging pathogens, this acquisition marks a pivotal step for Sanofi. The integration of Vicebio’s technology and pipeline not only complements Sanofi’s scientific strengths but also aligns with global health goals for broader, more efficient immunization strategies.
The deal highlights the increasing importance of biotech innovation, strategic partnerships, and technology-driven vaccine platforms in the future of global public health.